Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

Table 1

Demographics and baseline characteristics of patients enrolled into the immunology substudy of GRACE.

Parameter		All HIV+ patients; (𝑁=32)	Virologically suppressed^apatients at Wk 48 (𝑛=19)
Sex, 𝑛 (%)	Men	19 (59.4)	13 (68.4)
	Women	13 (40.6)	6 (31.6)
Race, 𝑛 (%)	Black	15 (46.9)	8 (42.1)
	Hispanic	10 (31.3)	6 (31.6)
	White	7 (21.9)	5 (26.3)
Mean (SD) viral load, log10 copies/mL		4.74 (0.84)	4.76 (0.82)
Median (range) CD4+ count, cells/mm^3		191 (2, 463)	222 (2, 398)

aHIV-1 RNA < 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available).